Amgen reports flat 2nd-qtr sales growth, but strong earnings
US biotech major Amgen (Nasdaq: AMGN) yesterday announced financial results for the second quarter of 2022.
Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, 1% above consensus expectations, resulting from 3% growth in global product sales partially offset by lower
Generally accepted accounting principles (GAAP) earnings per share (EPS) increased from $0.81 to $2.45driven by a decrease in operating expenses due to the write-off of $1.5 billion in acquired in-process research and development (Acquired IPR&D) associated with Amgen’s acquisition of Five Prime Therapeutics in second-quarter 2021 and lower weighted-average shares outstanding in second-quarter 2022, partially offset by an impairment charge related to the divestiture of Gensenta, a generics subsidiary in Turkey.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze